Fundraising FoxSilence Therapeutics
NASDAQ: SLNLondon · United Kingdom corporation · 4 known investors
Find your way into Silence Therapeutics
Sign up to see every warm intro you have to Silence Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Silence Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
Founders & leadership
Board
Investors · 4
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Vivo Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$45.5M disclosed across 1 round · 2021
▶$45.5MraisedFeb 2021 · 12 investors · BiotechnologyRule 506(b)
- James Ede-GolightlyDirector
- Alistair GrayDirector
- Craig ToomanExecutive Officer
- Dave LemusDirector
- Giles CampionExecutive Officer
- Romano StevenDirector
- Michael H. DavidsonDirector
- Mark RotheraExecutive Officer, Director
- Iain RossDirector
- Barbara RuskinExecutive Officer
- Offering amount
- $45.5M
- Amount sold
- $45.5M
- Sales commissions
- $2.7M
- Placement agents
- William Blair & Company, L.L.C.
- First sale
- Feb 2021
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 1
Early investors' stakes continue via these dealsDeveloped RNAi therapeutics; merged with Silence Therapeutics in December 2009.
In the news
Frequently asked questions
- What does Silence Therapeutics do?
- Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
- Who are Silence Therapeutics's investors?
- Silence Therapeutics's investors include Foresite Capital, MC Healthcare Ventures, Nextech Invest, Vivo Capital.
- How much funding has Silence Therapeutics raised?
- Silence Therapeutics has disclosed $45.5M raised across 1 round.
- Where is Silence Therapeutics headquartered?
- Silence Therapeutics is headquartered in London.